Boston Scientific Co. (NYSE:BSX) EVP Arthur C. Butcher Sells 14,011 Shares

Boston Scientific Co. (NYSE:BSXGet Free Report) EVP Arthur C. Butcher sold 14,011 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total value of $1,055,588.74. Following the sale, the executive vice president now owns 20,197 shares in the company, valued at approximately $1,521,641.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Boston Scientific Stock Up 0.0 %

Shares of NYSE:BSX opened at $75.00 on Friday. The company has a market capitalization of $110.03 billion, a price-to-earnings ratio of 63.03, a P/E/G ratio of 2.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The business’s 50-day moving average is $71.22 and its 200-day moving average is $64.35. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $76.25.

Boston Scientific (NYSE:BSXGet Free Report) last announced its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. The company had revenue of $3.86 billion for the quarter, compared to the consensus estimate of $3.68 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. Equities research analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in Boston Scientific by 5.6% during the 3rd quarter. Victory Capital Management Inc. now owns 518,047 shares of the medical equipment provider’s stock worth $27,353,000 after buying an additional 27,620 shares during the period. Louisiana State Employees Retirement System acquired a new position in Boston Scientific during the 4th quarter worth approximately $5,116,000. Glenmede Trust Co. NA raised its stake in Boston Scientific by 12.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock worth $551,000 after buying an additional 1,123 shares during the period. HealthInvest Partners AB acquired a new position in Boston Scientific during the 4th quarter worth approximately $3,746,000. Finally, Mackenzie Financial Corp raised its stake in Boston Scientific by 65.1% during the 4th quarter. Mackenzie Financial Corp now owns 708,833 shares of the medical equipment provider’s stock worth $40,978,000 after buying an additional 279,513 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on BSX. Needham & Company LLC boosted their price objective on Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Raymond James boosted their price objective on Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 25th. Mizuho boosted their price objective on Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. TD Cowen boosted their price objective on Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, March 7th. Finally, Oppenheimer boosted their price objective on Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, February 1st. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $76.70.

Get Our Latest Research Report on BSX

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Recommended Stories

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.